Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety

Malaria Journal

Volumn 16, Issue 1, 2017, Pages

  Chaccour, Carlos ^a,b,c   Hammann, Felix ^d   Rabinovich, N Regina ^a,e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Manhiça Health Research Center   (Mozambique)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anopheles; Endectocide; Ivermectin; Pharmacokinetics

Indexed keywords

ANION CHANNEL; GLUTAMATE GATED CHLORINE CHANNEL; IVERMECTIN; UNCLASSIFIED DRUG; INSECTICIDE;

ANOPHELES GAMBIAE; AREA UNDER THE CURVE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HUMAN; LC50; LOIASIS; MALARIA; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NONHUMAN; OCULAR ONCHOCERCIASIS; ONCHOCERCIASIS; PUBLIC HEALTH CAMPAIGN; REVIEW; SLOW DRUG RELEASE; UNSPECIFIED SIDE EFFECT; VECTOR CONTROL; ANIMAL; ANOPHELES; DRUG EFFECT; MOSQUITO CONTROL;

ANIMALS; ANOPHELES; INSECTICIDES; IVERMECTIN; MALARIA; MOSQUITO CONTROL;

EID: 85018573887     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-017-1801-4     Document Type: Review

References (105)

1. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207-11.
2. Durnez LC, Coosemans M. Residual transmission of malaria: an old issue for new approaches. In: Anopheles Mosquitoes-new insights into malaria vectors. Manguin S, editor. InTech; 2014.
3. Killeen GF. Characterizing, controlling and eliminating residual malaria transmission. Malar J. 2014;13:330.
4. Ranson H, Lissenden N. Insecticide resistance in African Anopheles mosquitoes: a worsening situation that needs urgent action to maintain malaria control. Trends Parasitol. 2016;32:187-96.
5. WHO. Global technical strategy for malaria 2016-2030. Geneva: World Health Organization. http://www.whoint/malaria/publications/atoz/9789241564991/en/. Accessed Feb 2017.
6. Shoop WL, Mrozik H, Fisher MH. Structure and activity of avermectins and milbemycins in animal health. Vet Parasitol. 1995;59:139-56.
7. Merck & Co. Stromectrol. FDA approved Package insert 2009. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/050742s026lbl.pdf. Accessed Oct 2016.
8. Merck & Co. Stromectrol. TGA-Australia approved Package insert 2014. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02659-3&d=2016071016114622483. Accessed Feb 2017.
9. Chaccour CJ, Kobylinski KC, Bassat Q, Bousema T, Drakeley C, Alonso P, et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J. 2013;12:153.
10. Foy BD, Kobylinski KC, da Silva IM, Rasgon JL, Sylla M. Endectocides for malaria control. Trends Parasitol. 2011;27:423-8.
11. Meyers JI, Gray M, Kuklinski W, Johnson LB, Snow CD, Black WC, et al. Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae. J Exp Biol. 2015;218:1478-86.
12. Menez C, Sutra JF, Prichard R, Lespine A. Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-/-) mice and effects on mammalian GABA(A) channel activity. PLoS Negl Trop Dis. 2012;6:e1883.
13. Fritz ML, Siegert PY, Walker ED, Bayoh MN, Vulule JR, Miller JR. Toxicity of bloodmeals from ivermectin-treated cattle to Anopheles gambiae s.l. Ann Trop Med Parasitol. 2009;103:539-47.
14. Gardner K, Meisch MV, Meek CL, Biven WS. Effects of ivermectin in canine blood on Anopheles quadrimaculatus, Aedes albopictus and Culex salinarius. J Am Mosq Control Assoc. 1993;9:400-2.
15. Edwards G, Dingsdale A, Helsby N, Orme ML, Breckenridge AM. The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Eur J Clin Pharmacol. 1988;35:681-4.
16. Gonzalez Canga A, Sahagun Prieto AM, Diez Liebana MJ, Fernandez Martinez N, Sierra Vega M, Garcia Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans-a mini-review. AAPS J. 2008;10:42-6.
17. Chiodini PL, Reid AJ, Wiselka MJ, Firmin R, Foweraker J. Parenteral ivermectin in Strongyloides hyperinfection. Lancet. 2000;355:43-4.
18. Marty FM, Lowry CM, Rodriguez M, Milner DA, Pieciak WS, Sinha A, et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis. 2005;41:e5-8.
19. Homeida MM, Malcolm SB, ElTayeb AZ, Eversole RR, Elassad AS, Geary TG, et al. The lack of influence of food and local alcoholic brew on the blood level of Mectizan((R)) (ivermectin). Acta Trop. 2013;127:97-100.
20. Miyajima A, Hirota T, Sugioka A, Fukuzawa M, Sekine M, Yamamoto Y, et al. Effect of high-fat meal intake on the pharmacokinetic profile of ivermectin in Japanese patients with scabies. J Dermatol. 2016;43:1030-6.
21. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, et al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010;38:D237-43.
22. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995;96:1698-705.
23. Vanapalli SR, Chen Y, Ellingrod VL, Kitzman D, Lee Y, Hohl RJ, et al. Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers. Clin Pharmacol Ther. 2003;73:P94.
24. Dowling P. Pharmacogenetics: it's not just about ivermectin in collies. Can Vet J. 2006;47:1165-8.
25. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491-502.
26. Jani M, Makai I, Kis E, Szabo P, Nagy T, Krajcsi P, et al. Ivermectin interacts with human ABCG2. J Pharm Sci. 2011;100:94-7.
27. Chiu SH, Lu AY. Metabolism and Tissue Residues. In: Campbell WC, editor. Ivermectin and abamectin. New York: Springer; 1989. p. 131-43.
28. Elkassaby MH. Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with Onchocerca volvulus. Trop Med Parasitol. 1991;42:79-81.
29. Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996;50:407-10.
30. Lam J, Baello S, Iqbal M, Kelly LE, Shannon PT, Chitayat D, et al. The ontogeny of P-glycoprotein in the developing human blood-brain barrier: implication for opioid toxicity in neonates. Pediatr Res. 2015;78:417-21.
31. Lankas GR, Minsker DH, Robertson RT. Effects of ivermectin on reproduction and neonatal toxicity in rats. Food Chem Toxicol. 1989;27:523-9.
32. Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998;28:313-21.
33. Treluyer JM, Cheron G, Sonnier M, Cresteil T. Cytochrome P-450 expression in sudden infant death syndrome. Biochem Pharmacol. 1996;52:497-504.
34. Treluyer JM, Gueret G, Cheron G, Sonnier M, Cresteil T. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in vivo/in vitro correlation and inducibility. Pharmacogenetics. 1997;7:441-52.
35. Chiu SH, Taub R, Sestokas E, Lu AY, Jacob TA. Comparative in vivo and in vitro metabolism of ivermectin in steers, sheep, swine, and rat. Drug Metab Rev. 1987;18:289-302.
36. Fink DW, Porras AG. Pharmacokinetics of ivermectin in animals and humans. In: Campbell WC, editor. Ivermectin and abamectin. New York: Springer; 1989. p. 113-30.
37. Kobylinski K, Davidson S, Jittamala P, Pukrittayakamee S, Hanboonkunupakarn B, van der Pluijm R, et al. Mosquito-lethal efficacy of ivermectin, dihydroartemisinin-piperaquine, and primaquine: Ivermectin for Malaria in Southeast Asia (IMSEA Study). Oral presentation during the 65th Annual Meeting of the ASTMH Atlanta 2016. 2016.
38. Smit M, Ochomo E, ter Kuile F. Efficacy and safety of high-dose ivermectin for reducing malaria transmission: A dose finding study (IVERMAL). Oral presentation during the 65th Annual Meeting of the ASTMH Atlanta 2016.
39. Lespine A, Menez C, Bourguinat C, Prichard RK. P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: prospects for reversing transport-dependent anthelmintic resistance. Int J Parasitol Drugs Drug Resist. 2012;2:58-75.
40. Alvinerie M, Dupuy J, Kiki-Mvouaka S, Sutra JF, Lespine A. Ketoconazole increases the plasma levels of ivermectin in sheep. Vet Parasitol. 2008;157:117-22.
41. Hugnet C, Lespine A, Alvinerie M. Multiple oral dosing of ketoconazole increases dog exposure to ivermectin. J Pharm Pharm Sci. 2007;10:311-8.
42. Ouedraogo AL, Bastiaens GJ, Tiono AB, Guelbeogo WM, Kobylinski KC, Ouedraogo A, et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin Infect Dis. 2015;60:357-65.
43. Smit MR, Ochomo E, Aljayyoussi G, Kwambai T, Abong'o B, Bayoh N, et al. Efficacy and safety of high-dose ivermectin for reducing malaria transmission (IVERMAL): protocol for a double-blind, randomized, placebo-controlled, dose-finding trial in Western Kenya. JMIR Res Protoc. 2016;5:e213.
44. Chaccour CJ, Rabinovich NR, Slater H, Canavati SE, Bousema T, Lacerda M, et al. Establishment of the ivermectin research for malaria elimination network: updating the research agenda. Malar J. 2015;14:243.
45. Kobylinski KC, Deus KM, Butters MP, Hongyu T, Gray M, da Silva IM, et al. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 2010;116:119-26.
46. Kobylinski KC, Foy BD, Richardson JH. Ivermectin inhibits the sporogony of Plasmodium falciparum in Anopheles gambiae. Malar J. 2012;11:381.
47. Sylla M, Kobylinski KC, Gray M, Chapman PL, Sarr MD, Rasgon JL, et al. Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malar J. 2010;9:365.
48. Seaman JA, Alout H, Meyers JI, Stenglein MD, Dabire RK, Lozano-Fuentes S, et al. Age and prior blood feeding of Anopheles gambiae influences their susceptibility and gene expression patterns to ivermectin-containing blood meals. BMC Genom. 2015;16:797.
49. Slater H, Kobylinski KC, Foy B, Alout H, Churcher T, Bousema T, Ghani A. Ivermectin for malaria control: model validation to existing data and designing trials to detect an impact using clinical and entomological metrics. In 64th Annual meeting of the American Society of Tropical Medicine and Hygiene; 2015 Oct 25-29; Philadelphia.
50. Slater HC, Walker PG, Bousema T, Okell LC, Ghani AC. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. J Infect Dis. 2014;210:1972-80.
51. Foy BD, Alout H, Seaman JA, Coulidiaty AGV, Bougma R, Rouamba N, et al. Update on Repeat Ivermectin Mass Drug Administrations for control of MALaria (RIMDAMAL): a randomized pilot safety and efficacy study (poster). In: 64th annual meeting of the American Society of Tropical Medicine and Hygiene 2015 Philadelphia, USA.
52. Bellinger AM, Jafari M, Grant TM, Zhang S, Slater HC, Wenger EA, et al. Oral, ultra-long-lasting drug delivery: application toward malaria elimination goals. Sci Transl Med. 2016;8:365ra157.
53. Chaccour C, Barrio A, Gil Royo AG, Martinez Urbistondo D, Slater H, Hammann F, et al. Screening for an ivermectin slow-release formulation suitable for malaria vector control. Malar J. 2015;14:102.
54. International Transporter C, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-36.
55. Butters MP, Kobylinski KC, Deus KM, da Silva IM, Gray M, Sylla M, et al. Comparative evaluation of systemic drugs for their effects against Anopheles gambiae. Acta Trop. 2012;121:34-43.
56. Kobylinski K, Ubalee R, Ponlawat A, McCardle W, Foy B, Szumlas D, et al. Ivermectin inhibits the development of Plasmodium vivax in Anopheles dirus. 64th Annual meeting of the American Society of Tropical Medicine and Hygiene; 2015 Oct 25-29; Philadelphia USA.
57. da Cruz FP, Martin C, Buchholz K, Lafuente-Monasterio MJ, Rodrigues T, Sonnichsen B, et al. Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J Infect Dis. 2012;205:1278-86.
58. Pinilla Y, Lopes S, Fabri C, Sampaio V, Melo G, Lacerda M, et al. Effect of ivermectin on Plasmodium vivax in its interaction with Anopheles aquasalis (poster). 65th Annual meeting of the American Society of Tropical Medicine and Hygiene; 2016 Nov 11-17; Atlanta, USA.
59. Mectizan Donation Program. Annual highlights 2015. http://www.mectizan.org/sites/www.mectizan.org/files/attachments/resources/MDP-AnnHigh2015-Design%20041516FINAL2%20%281%29.pdf. Accessed Aug 2016.
60. Burrows JN, van Huijsduijnen RH, Mohrle JJ, Oeuvray C, Wells TN. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013;12:187.
61. Golan DT, AH; Armstrong, EJ; Armstrong, AW. Principles of pharmacology: the pathophysiologic basis of drug therapy, 3rd Ed. Philadelphia. USA: LWW; 2011.
62. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42:1122-33.
63. Centers for disease control and prevention (CDC). Prescription medication for the treatment of scabies. http://www.cdc.gov/parasites/scabies/health-professionals/meds.html. Accessed June 2016.
64. WHO. Preventive chemotherapy in human helminthiasis. Coordinated use of anthelminthic drugs in control interventions. A manual for health professionals and programme managers. http://apps.who.int/iris/bitstream/10665/43545/1/9241547103-eng.pdf. Accessed Aug 2016.
65. APOC. Conceptual and operational framework of onchocerciasis elimination with ivermectin treatment. 2010. http://www.whoint/apoc/oncho-elimination-report-englishpdf. Accessed Aug 2015.
66. Mackenzie CD, Geary TG, Gerlach JA. Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients. Filaria J. 2003;2(Suppl 1):S5.
67. Kamgno J, Gardon J, Gardon-Wendel N, Demanga N, Duke BO, Boussinesq M. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Trans R Soc Trop Med Hyg. 2004;98:496-504.
68. Njoo FL, Beek WM, Keukens HJ, van Wilgenburg H, Oosting J, Stilma JS, et al. Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions. Am J Trop Med Hyg. 1995;52:94-7.
69. Ejere HO, Schwartz E, Wormald R, Evans JR. Ivermectin for onchocercal eye disease (river blindness). Cochrane Database Syst Rev. 2012;8:CD002219.
70. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350:18-22.
71. Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J. 2003;2(Suppl 1):S8.
72. The Mectizan Expert Committee and The Technical Consultative Committee. Recommendations for the treatment of Onchocerciasis with Mectizan in areas co-endemic for Onchocerciasis and Loiasis. http://www.who.int/apoc/publications/englishmectccloarecs-june04.pdf. Accessed July 2016.
73. Zoure HG, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis. 2011;5:e1210.
74. D'Ambrosio MV, Bakalar M, Bennuru S, Reber C, Skandarajah A, Nilsson L, et al. Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope. Sci Transl Med. 2015;7:286re4.
75. Drame PM, Meng Z, Bennuru S, Herrick JA, Veenstra TD, Nutman TB. Identification and validation of Loa loa microfilaria-specific biomarkers: a rational design approach using proteomics and novel immunoassays. MBio. 2016;7:e02132.
76. Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of Bancroftian filariasis. Clin Infect Dis. 2016;62:334-41.
77. Ministere des affaires sociales de la sante et des droits des femmes. STROMECTOL 3 mg, comprimé-Résumé des caractéristiques du produit. http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61350360. Accessed Aug 2016.
78. MedicineWise N. Ivermectin (Stromectol) for typical and crusted scabies. 2014. Radar, https://www.npsorgau/radar/articles/ivermectin-stromectol-for-typical-and-crusted-scabies. Accessed Aug 2016.
79. RIMDAMAL. Study information available at Clinicaltrials.org. https://clinicaltrials.gov/ct2/show/NCT02509481?term=rimdamal&rank=1. Accessed Aug 2015.
80. FDA. Center for drug evaluation and research. Approval package for Mectizan. http://www.accessdata.fda.gov/drugsatfda-docs/nda/96/050742ap.pdf. Accessed July 2016.
81. Pacque M, Munoz B, Poetschke G, Foose J, Greene BM, Taylor HR. Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet. 1990;336:1486-9.
82. Brown KR. Changes in the use profile of Mectizan: 1987-1997. Ann Trop Med Parasitol. 1998;92(Suppl 1):S61-4.
83. Ogbuokiri JE, Ozumba BC, Okonkwo PO. Ivermectin levels in human breastmilk. Eur J Clin Pharmacol. 1993;45:389-90.
84. Chaccour C, Rabinovich NR. Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway. Malaria J (submitted).
85. Chaccour CJ, Del Pozo JL. Case 23-2012: a man with abdominal pain and weight loss. N Engl J Med. 2012;367:1670-1.
86. Roberts LJ, Huffam SE, Walton SF, Currie BJ. Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J Infect. 2005;50:375-81.
87. Becourt C, Marguet C, Balguerie X, Joly P. Treatment of scabies with oral ivermectin in 15 infants: a retrospective study on tolerance and efficacy. Br J Dermatol. 2013;169:931-3.
88. Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet. 1997;349:1144-5.
89. Bredal WP. Deaths associated with ivermectin for scabies. Lancet. 1997;350:216.
90. Coyne PE, Addiss DG. Deaths associated with ivermectin for scabies. Lancet. 1997;350:215-6 (author reply 16).
91. Currie B, Huffam S, O'Brien D, Walton S. Ivermectin for scabies. Lancet. 1997;350:1551.
92. Reintjes R, Hoek C. Deaths associated with ivermectin for scabies. Lancet. 1997;350:215 (author reply 16).
93. Australian Government: Department of health. Therapeutic goods administration. Australian Public Assessment Report for Ivermectin. 2013. https://www.tga.gov.au/sites/default/files/auspar-ivermectin-131030.docx. Accessed Aug 2016.
94. Dukuly ZD, Pacque M, Nara A, Taylor HR, Williams PN, Greene BM. A prospective study in high risk subjects of electrocardiographic changes with ivermectin. Trop Med Parasitol. 1990;41:73-4.
95. Kipp W, Burnham G, Kamugisha J. Improvement in seizures after ivermectin. Lancet. 1992;340:789-90.
96. Halley BA, VandenHeuvel WJ, Wislocki PG. Environmental effects of the usage of avermectins in livestock. Vet Parasitol. 1993;48:109-25.
97. Wall R, Strong L. Environmental consequences of treating cattle with the antiparasitic drug ivermectin. Nature. 1987;327:418-21.
98. Barth D, Heinze-Mutz EM, Langholff W, Roncalli RA, Schluter D. Colonisation and degradation of dung pats after subcutaneous treatment of cattle with ivermectin or levamisole. Appl Parasitol. 1994;35:277-93.
99. MPAC meeting, 14-16 September 2016: Update on a proposed Ivermectin target product profile. http://www.whoint/entity/malaria/mpac/mpac-sept2016-invermectin-session9pdf?ua=1. Accessed March 2017.
100. Awadzi K, Opoku NO, Addy ET, Quartey BT. The chemotherapy of onchocerciasis. XIX: the clinical and laboratory tolerance of high dose ivermectin. Trop Med Parasitol. 1995;46:131-7.
101. Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT. The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients. Trans R Soc Trop Med Hyg. 1999;93:189-94.
102. Doumbo O, Soula G, Kodio B, Perrenoud M. Ivermectin and pregnancy in mass treatment in Mali (in French). Bull Soc Pathol Exot. 1992;85:247-51.
103. Chippaux JP, Gardon-Wendel N, Gardon J, Ernould JC. Absence of any adverse effect of inadvertent ivermectin treatment during pregnancy. Trans R Soc Trop Med Hyg. 1993;87:318.
104. Gyapong JO, Chinbuah MA, Gyapong M. Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis. Trop Med Int Health. 2003;8:1093-101.
105. Ndyomugyenyi R, Kabatereine N, Olsen A, Magnussen P. Efficacy of ivermectin and albendazole alone and in combination for treatment of soil-transmitted helminths in pregnancy and adverse events: a randomized open label controlled intervention trial in Masindi district, western Uganda. Am J Trop Med Hyg. 2008;79:856-63.